The GISAID antiviral characterization sheet for A/Kansas/05/2010 has been corrected as indicated above.
The initial sheet (posted yesterday) indicated (see list here) the isolate was resistant to Oseltamivir (Tamiflu) and Zanamivir (Relenza).
This morning the CDC contacted Recombinomics to indicate the entry was in error and likely linked to the recent GISAID upgrade of the site (which now allows BLAST analysis of the database).
BTA Price at posting:
91.5¢ Sentiment: LT Buy Disclosure: Held